Form 4: Precigen Chief Legal Officer Granted 250,000 Stock Options

Precigen, Inc.'s Chief Legal Officer, Donald P. Lehr, was granted 250,000 stock options with an exercise price of $1.37, vesting over a four-year period.

Summary

• Donald P. Lehr, Chief Legal Officer of Precigen, Inc. (PGEN), was granted 250,000 options to purchase common stock.
• The transaction date for this grant was May 23, 2025.
• The exercise price for these options is $1.37 per share.
• The options will vest 50% on May 23, 2026, with the remaining balance vesting in equal monthly installments over the subsequent three years.
• The options have an expiration date of May 23, 2035.
• Following this transaction, Donald P. Lehr beneficially owns 250,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options is generally positive as it aligns management incentives with shareholder interests, promoting long-term value creation. It is a standard compensation practice.

Positives

• The grant of stock options aligns the interests of the Chief Legal Officer with those of shareholders, incentivizing long-term company performance and stock price appreciation.
• Stock options are a common and effective tool for executive compensation, helping to attract and retain key talent.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

• If Precigen's common stock price does not rise above the $1.37 exercise price, the granted options may become 'out-of-the-money' and lose their intrinsic value, potentially reducing their effectiveness as an incentive.
• The value of the options is subject to market fluctuations and the overall performance of Precigen's stock.

Future Outlook

The grant of these stock options suggests a continued commitment to aligning executive incentives with long-term shareholder value creation, as the options' value is tied to future stock price performance.

Industry Context

The granting of stock options to key executives is a standard practice across various industries, particularly in biotechnology and pharmaceuticals, to incentivize performance and retain talent. This aligns with typical compensation structures seen in publicly traded companies.

Comparison to Industry Standards

• The use of stock options as a component of executive compensation is a widely accepted practice, consistent with global benchmarks for corporate governance and incentive alignment.
• The vesting schedule, with an initial cliff and subsequent monthly installments, is a common structure designed to encourage long-term retention and performance.

Related Party Transactions

• This transaction represents a related party dealing, as it involves the company granting equity compensation to one of its executive officers, Donald P. Lehr.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned management incentives for long-term stock performance.
• Employees: This grant is part of the company's executive compensation strategy, which can influence overall employee morale and retention strategies.

Next Steps

• The options will begin vesting on May 23, 2026, with 50% vesting, followed by monthly vesting over the subsequent three years.
• Donald P. Lehr may choose to exercise these options at any time after they vest and before their expiration date of May 23, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Precigen, PGEN, Stock Options, Executive Compensation, SEC Form 4, Insider Transaction, Derivative Securities, Chief Legal Officer, Equity Grant